[ A21-110] Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

Last updated 03.03.2022

Project no.:
A21-110

Commission:
Commission awarded on 15.09.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Indication:

Adult patients with moderate to severe plaque psoriasis

Result of dossier assessment:
  • Patients who are not candidates for conventional treatment in the framework of an initial systemic therapy: hint of minor added benefit.
  • Patients who have had an inadequate response or who have been intolerant to systemic therapy: added benefit not proven.
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-12-15.

Federal Joint Committee (G-BA)

2022-03-03 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form